Gilde Healthcare company Nalu appoints Thomas West as new president and CEO - Gilde Healthcare

Gilde Healthcare company Nalu appoints Thomas West as new president and CEO

19. Juli 2022
Utrecht (Niederlande) und Cambridge (Vereinigte Staaten)

Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced that the Board of Directors has appointed Thomas “Tom” West as President and Chief Executive Officer.
This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu’s current CEO, to retire. Mr. Fender will remain as a consultant to the company for the next 12 months.

Mr. West remarked, “I am very excited and honored to be leading Nalu. I believe Nalu’s unique system and technology, including the miniaturized, battery-free implantable pulse generator with its broad capabilities, upgradability and industry leading longevity are going to meaningfully expand the number of chronic pain patients who can benefit from both Spinal Cord and Peripheral Nerve Stimulation. Nalu is poised for rapid growth, and I am eager to join the company and to build upon the strong foundation it has established.”

Mr. Fender added, “I am proud of the Nalu team and what we have accomplished to date. The company is in a strong position and the timing is right for me to retire. We are very fortunate to have someone of Tom’s caliber joining the team. Tom has a proven track record of leading and building strong teams during high periods of growth. He has more than 30 years of medical device leadership experience, including as Division President, Diagnostic Solutions at Hologic, and most recently as the President and CEO of Intersect ENT (NASDAQ: XENT) prior to its recent sale to Medtronic. Tom began his healthcare career at Johnson & Johnson and serves as an independent member of the board of directors at Orthofix. He is very focused on customers and clinical outcomes, which are at the heart of Nalu’s success.”

Speaking on behalf of the Board, its Chairman, Geoff Pardo, said, “we are very grateful for Earl’s leadership, particularly in leading the recent $104M equity financing and establishing a strong foundation for the company’s continued growth. We wish him well in his retirement. The Board is very excited that Tom has joined the company. He is a visionary leader and we believe his commercial and operational skills and experience are what Nalu needs for its next phase of growth.”

About Nalu Medical
Nalu is a Carlsbad, California-based medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain. The Nalu Neurostimulation System delivers gentle electrical pulses to the nervous system to modulate pain signals before they get to the brain. The Nalu system was designed to address major unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians. To learn more, visit www.nalumed.com.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over $2 billion across two fund strategies: Private Equity and Venture&Growth. The firm is headquartered in Utrecht (The Netherlands) with local offices in Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare’s Venture&Growth fund invests in therapeutics, medtech and healthtech in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. Further information at www.gildehealthcare.com

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate...
21. März 2024

Gilde Healthcare veräussert RAD-x an ein konsortium aus Swiss Life Asset Managers und Vesper Infrastructure Fund I

Gilde Healthcare´s Private Equity Fund (“Gilde Healthcare”), ein auf das Gesundheitswesen spezialisierter Investor, hat eine bindende Vereinbarung über den Verkauf seiner Mehrheitsbeteiligung an RAD-x an ein Konsortium aus Swiss Life Asset Managers und Vesper Next...
18. März 2024

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
29. Februar 2024